
Lipocine (LPCN) Stock Forecast & Price Target
Lipocine (LPCN) Analyst Ratings
Bulls say
Lipocine Inc. is advancing its pharmaceutical pipeline with promising data from LPCN 1154, an oral formulation of brexanolone, which exhibits improved efficacy and safety characteristics compared to zuranolone, including a rapid onset of action and a substantial remission rate of 61% by Day 3. The company's approach to drug delivery through proprietary technology positions it favorably within the biopharmaceutical landscape, with implications for future regulatory approvals, as evidenced by its plans to submit a 505(b)(2) new drug application based on the positive topline data. Despite a reported net loss of $3.2 million, the increase in the probability of LPCN 1154's approval to 50% reflects optimism about its potential market impact and the overall strategic direction of Lipocine.
Bears say
Lipocine Inc. reported a net loss of $3.2 million in the third quarter of 2025, highlighting ongoing financial challenges as the company continues its focus on research and development. The company faces multiple risks related to its product pipeline, particularly concerning LPCN 1154, including potential failures in clinical trials, regulatory approval, and market competition that could impact commercial success. Additionally, the threat of dilution presents further financial concerns that could negatively affect shareholder value and confidence.
This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.
Lipocine (LPCN) Analyst Forecast & Price Prediction
Start investing in Lipocine (LPCN)
Order type
Buy in
Order amount
Est. shares
0 shares